Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection. ・Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection ...

For the first time ever, a patient has received an allogeneic stem cell transplant using a deceased donor graft as part of a blood cancer clinical trial at Huntsman Cancer Institute at the University ...

Stem cells form the backbone of many cell-based therapies due to their unique properties, including the ability to self-renew and differentiate to many cell types. Multiple cell therapies deliver ...

Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors on HPCs, rapidly mobilizing these cells from the bone marrow into the peripheral blood. In preclinical ...

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a critical therapeutic strategy for treating conditions such as hematological malignancies, bone marrow failure syndromes, and ...